menu
    • menu

    PDF presentation for Beijing Mesochem Technology

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    EXCIPIENTS

    EXCIPIENTS BY INGREDIENTS

    EXCIPIENTS BY APPLICATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine chemicals and fundamental chemical materials. It has an efficient research and development team. Beijing Mesochem provides its customers customized development, craft optimization, contract customization and outsourcing services. The company has a wel...
    Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine chemicals and fundamental chemical materials. It has an efficient research and development team. Beijing Mesochem provides its customers customized development, craft optimization, contract customization and outsourcing services. The company has a well-established industrial base in Weinan, Shanxi Province. The production base features a 20,000 ㎡ plant with a production capacity of over 8,000 MT per year.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Beijing Mesochem TechnologyChina Flag
    Country
    Country
    China
    Address
    Address
    Floor 23, Building 9, Lippo Plaza, Economic and Technological Development Zone...
    Telephone
    Telephone
    +86 15652159054
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.mesochem.com/en/index.asp
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    CPhI Worldwide, Milan

    CPhI Worldwide, Milan

    Not Confirmed

    envelop Contact Supplier

    CPhI Worldwide, Milan

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “We’re unlocking life-changing potential in complex molecules, without sacrificing time to market”

    “We’re unlocking life-changing potential in complex molecules, without sacrificing time to market”

    This week, SpeakPharma interviews Mike Riley, CEO of Veranova, a leading contract development and manufacturing organization (CDMO) confidently mastering complex APIs as it marks its second year as an independent company. Riley discusses Veranova’s key achievements, including a US$ 30 million investment in their Devens, Massachusetts (US) site to expand capabilities in antibody-drug conjugates (ADCs) and highly potent APIs (HPAPIs), and how it is navigating the increasing complexity of molecules. 🔑 HIGHLIGHTS// Veranova’s key achievements / navigating the increasing complexity of molecules Veranova is celebrating its second year as a stand-alone company. Can you share Veranova’s key milestones and achievements in its first two years? We have achieved incredible milestones over the last two years, thanks to the dedication and hard work of our team. Our first 12 months focused on establishing ourselves as an independent CDMO by building on the 50 years of expertise that we brought with us. In addition, we expanded our capabilities and applied a more agile approach available to us as a company singularly focused on life sciences. This has allowed us to move into our second year with clear and strategic goals for generating growth in our sites, people, capabilities, and offerings. Since being appointed as CEO in May 2023, I’ve had the pleasure of witnessing some exciting growth milestones of my own. Most recently, we announced an estimated US$ 30 million investment in our Devens, Massachusetts, site. This expansion will allow us to build upon existing development and manufacturing capabilities in ADCs and HPAPIs that will address the growing demand for strong US-based capacity in these key drug modalities. We also appointed our Advisory Board, thereby bolstering Veranova’s in-house expertise. Made up of four distinguished leaders in pharma and biopharma – including Dr. Carolyn Bertozzi, the 2022 Nobel Laureate in Chemistry – the Board has provided thought-leadership, guidance and expertise as we develop and execute our strategic growth and ideas. We were also proud to be recognized as one of the Society of Chemical Manufacturers and Affiliates’ 12 companies for industry-leading safety programs in 2023 and as a part of the Medicine Maker’s Power List in 2024. 🔑 HIGHLIGHTS// US$ 30 million investment in our Devens, Massachusetts, site / appointed our Advisory Board Molecules are becoming increasingly complex. Can you elaborate on how Veranova’s current capabilities are strategically designed to address this trend in the coming years? The pharmaceutical pipeline is witnessing an increasing number of complex and highly potent molecules. This trend is driven by the demand for more targeted, patient-centric therapeutics and the focus on innovative modalities such as ADCs and other bioconjugates. At Veranova, our expertise, world-class facilities, and scientific excellence enable us to provide our customers with the clarity and solutions needed to manage this development and manufacturing complexity and ultimately deliver the required treatments to customers and patients. Our people are key to this approach. We have an expert team ready to collaborate with customers at any point, from early development through large-scale commercial production. Our services include world-leading crystallization development, process development, and specialized manufacturing expertise for complex synthetic molecules, including those requiring chromatography capabilities. In many cases, we can provide all these under one roof. Our service offering to our customers is also based on the foundational element of strong quality and compliance systems. We operate multiple facilities approved by the US FDA, UK’s MHRA and other regulatory authorities and are continually focused on ways to strengthen our global quality management system. Looking ahead, we are focused on continually investing in our facilities and team to meet growing complexity, as evidenced by our recent announcement of new investment in our Devens site. This investment signals our commitment to providing state-of-the-art capacity and capabilities to enable these next-generation therapies to reach patients. It is a key milestone as we advance Veranova’s broader growth strategy. 🔑 HIGHLIGHTS// provide our customers with clarity and solutions / world-leading crystallization development / expertise for complex synthetic molecules / strong quality and compliance systems How is Veranova approaching the challenge of designing and manufacturing effective linker molecules for ADCs? As a leader in complex linker-payload synthesis, Veranova is committed to unlocking the life-changing potential of ADCs without letting their complexities slow down the development of much-needed cancer therapies. ADCs are intricate, multi-component molecules that require extensive expertise and agile collaboration to overcome unique development challenges. With over a decade of experience in ADC linker-payload systems, we have developed the ability to anticipate challenges and avoid common pitfalls. The ADC linker-payload components are complex structures that are difficult to crystallize and require specialized high-potent handling. Veranova’s differentiated combination of world-leading crystallization development capabilities, complex synthesis experience, chromatography expertise and high-potent-handling experience put us in a unique position to solve these challenges for customers and speed their products to the clinic. We prioritize getting it right the first time, minimizing change orders and ensuring high-quality results. We have developed a robust phase-appropriate strategy that is backed by state-of-the-art analytical equipment and regulatory procedures to ensure our partners can rapidly progress their ADC projects from pre-clinical to commercialization. 🔑 HIGHLIGHTS// unlocking the life-changing potential of ADCs / ensuring our partners can rapidly progress their ADC projects Can you specify how Veranova is using artificial intelligence (AI) to optimize manufacturing processes that can reduce costs and environmental footprint as well as speed up development? In May 2024, Veranova announced a partnership with Phorum.AI to leverage AI to optimize pharmaceutical manufacturing processes. This collaboration aims to enable the rapid development of processes that can drive efficiency and reduce costs while maximizing environmental sustainability. Our goal is to combine Veranova’s extensive empirical manufacturing dataset of owned APIs and drug master files with Phorum.AI’s computational chemistry engine in order to create a more powerful process-development tool for the benefit of Veranova’s and Phorum’s customers. At Veranova, we are constantly looking to employ innovative technologies and approaches to improve efficiency, accelerate time to market and reduce environmental footprint. We have the means to work with a variety of partners who have unique project requirements, without sacrificing time to market.  🔑 HIGHLIGHTS// partnership with Phorum.AI / create a more powerful process-development tool / improve efficiency, accelerate time to market and reduce environmental footprint

    Impressions: 1632

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/we-re-unlocking-life-changing-potential-in-complex-molecules-without-sacrificing-time-to-market

    #SpeakPharma With Veranova
    10 Sep 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination

    Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination

    The pharmaceutical industry has long recognized the critical role excipients or inactive ingredients play in drug formulation and delivery. Excipients can comprise up to 90 percent of a medicine's total ingredients and serve crucial functions as binders, disintegrants, coatings, preservatives, colors, and flavorings. According to recent market research, the pharmaceutical excipients market was valued at US$ 9.27 billion in 2023. It is growing at a compound annual growth rate (CAGR) of 7.03 percent and is projected to reach US$ 18.48 billion by 2032. The main factors driving market growth is an increased demand for multifunctional excipients, coupled with the expanding use of generic medications. The development in the biologics sector and advancements in nanotechnology are also contributing significantly to market growth. Major excipient providers include BASF, Evonik, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, Roquette Frères, DuPont, Croda International, Seqens, Boai NKY Pharmaceuticals, PMC Isochem, Minakem, Kewpie Corporation, Ashland Global, SPI Pharma, Pfanstiehl, Nanjing Well Pharmaceutical, ICE Pharma, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) WHO, India’s CDSCO tighten regulations; new GMP guidelines implemented to curb contamination Last year, the World Health Organization (WHO) issued a health alert linking at least 300 child deaths in the Gambia, Uzbekistan, and Indonesia to the ingestion of contaminated cough syrups containing unacceptable levels of diethylene glycol (DEG) and ethylene glycol (EG). In response to the tragic events, the WHO released two draft appendices to its guideline on good manufacturing practices (GMPs) for excipients this year. Manufacturers are now required to use suitable risk assessment tools to identify and mitigate potential hazards.  Since India-made cough syrups had been linked to the deaths, India’s drug regulator — Central Drugs Standard Control Organization (CDSCO) — took steps to prevent contamination, and advised drugmakers to only use pharmaceutical-grade excipients from approved sources. Furthermore, the Indian Health Ministry proposed amendments to the Drugs and Cosmetics Rules, 1945 to include details of excipients on drug labels. While listing all excipients on every strip of medicine may be challenging, the ministry suggested mentioning those causing hypersensitivity on the label. Applicants now mandatorily need to submit evidence of stability and safety of excipients. These regulatory developments have significant implications for excipient manufacturers and pharmaceutical companies worldwide. Leading pharmaceutical excipient firms like Gangwal Healthcare, Sigachi Industries, and Nitika Pharmaceuticals are well-positioned to meet these heightened quality and safety standards, given their long-standing commitment to producing high-quality, compliant excipients.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Roquette buys IFF’s pharma unit for US$ 2.85 bn; Evonik opens new spray-drying facility in Darmstadt In a significant industry move, France-based Roquette entered into an agreement to acquire IFF's pharma solutions business in a deal valued at US$ 2.85 billion. This acquisition is set to rebalance family-owned Roquette’s portfolio around health and nutrition. The deal is expected to accelerate Roquette’s growth and significantly strengthen its presence in the excipients market. Evonik has opened a new facility for drying aqueous dispersions of its Eudragit polymers at its site in Darmstadt, Germany. The facility will help Evonik meet increasing demand from drugmakers for its oral drug delivery solutions. The plant uses green energy solutions. The company has also partnered University of Mainz to commercialize a new class of polyethylene glycols (PEG) lipids for nucleic acid delivery. Evonik’s Health Care business has been growing its nucleic acid drug and vaccine delivery portfolio.  Germany’s Johannes Gutenberg University of Mainz was the first to develop randomized polyethylene glycols (rPEGs). This collaboration aims to expand Evonik’s toolbox of technologies for nucleic acid-based medicines, offering an improved immunogenicity profile for lipid nanoparticle carriers used in mRNA vaccines and therapeutics. Asahi Kasei made significant strides in addressing a pressing industry concern that emerged in 2018 when potentially carcinogenic nitrosamine impurities were detected in several pharmaceuticals. Guided by regional authorities, such as the European Medicines Agency and the US Food and Drug Administration, the pharmaceutical industry has been carrying out extensive assessments and research to identify the cause of these impurities. In response to this challenge, Asahi Kasei developed its Ceolus microcrystalline cellulose with extremely low nitrite levels. The Japanese company achieved nitrite concentrations of 0.1 micrograms per gram or less, which is equivalent to 0.1 parts per million (ppm). The company also started full commercial operation of its second manufacturing facility for Ceolus in Japan, enhancing supply capacity and stability. JRS Pharma and Gujarat Microwax opened a state-of-the-art cotton-based croscarmellose sodium plant in Mehsana, Gujarat (India). This facility aims to produce high-quality excipients that meet global standards, potentially reducing India's dependency on imports and boosting its presence in the global excipient market. The Indian excipient industry accounts for less than 1 percent of the global market share.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Seqens to advance innovative polymer; biologics, personalized medicine create demand for specialized excipients Recent industry collaborations highlight the ongoing innovation in novel excipients. France’s Seqens, with over 20 years of polymer development experience, was chosen by Pleryon Therapeutics to advance its leading osteoarthritis candidate – an innovative GMP polymer. This collaboration leverages Seqens’ newly expanded and modernized cGMP plant in Aramon, France, demonstrating the industry’s commitment to investing in advanced manufacturing capabilities for novel excipients.  The rise of biologics and personalized medicine has created a demand for specialized excipients capable of stabilizing complex molecules and enabling targeted drug delivery. Roquette’s launch of Lycagel Flex, a hydroxypropyl pemix for nutraceutical and pharmaceutical softgel capsules, exemplifies this trend. Built on Roquette’s market-first Lycagel pea starch technology, this plant-based alternative to gelatin offers manufacturers the flexibility to customize formulations for a range of production and end-user needs. The innovative pea starch foundation also underscores the industry’s move towards sustainable bio-based excipients. The trend towards patient-centric drug development has also influenced excipient innovation. Excipients that can improve palatability, ease of swallowing, or enable novel dosage forms (such as orally disintegrating tablets) are in high demand. For example, IFF brought a super disintegrant Ac-Di-Sol, that supports faster disintegration and drug dissolution in oral disintegrating tablets, improving patient experience.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Our view The heightened regulatory scrutiny on excipients due to product contamination incidents has created a high risk perception and uncertainty around the regulatory acceptance of novel excipients. That said, novel excipients are central to the development of new drug modalities and therapies. Going forward, sustainability will also become an increasingly important factor in excipient selection and development. As the industry innovates towards biologics, personalized therapies, and patient-centric formulations, the role of high-quality, multifunctional excipients will only grow more vital in ensuring drug stability, bioavailability, and patient compliance. Companies that can navigate the complex regulatory landscape, invest in R&D, and offer high-quality, multifunctional excipients will be well-positioned to succeed in this evolving market.   
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 662

    https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-seqens-evonik-make-strategic-moves-new-guidelines-deal-with-contamination

    #PharmaFlow by PHARMACOMPASS
    12 Sep 2024
    Share Share

    Excipients

    Upload your portfolio for free, ask us

    Excipients by Ingredients

    Upload your portfolio for free, ask us

    Excipients By applications

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Contact Beijing Mesochem Technology and get a quotation

    Beijing Mesochem Technology is a supplier offers 117 products (APIs, Excipients or Intermediates).

    Find a price of Empagliflozin bulk with DMF offered by Beijing Mesochem Technology

    Find a price of Tofacitinib Citrate bulk with DMF offered by Beijing Mesochem Technology

    Find a price of Abemaciclib bulk offered by Beijing Mesochem Technology

    Find a price of Acalabrutinib bulk offered by Beijing Mesochem Technology

    Find a price of Adapalene bulk offered by Beijing Mesochem Technology

    Find a price of Afatinib bulk offered by Beijing Mesochem Technology

    Find a price of Alectinib Hydrochloride bulk offered by Beijing Mesochem Technology

    Find a price of Alpelisib bulk offered by Beijing Mesochem Technology

    Find a price of Ambrisentan bulk offered by Beijing Mesochem Technology

    Find a price of Apalutamide bulk offered by Beijing Mesochem Technology

    Find a price of Apremilast bulk offered by Beijing Mesochem Technology

    Find a price of Atracurium Besylate bulk offered by Beijing Mesochem Technology

    Find a price of Avatrombopag Maleate bulk offered by Beijing Mesochem Technology

    Find a price of Avibactam Sodium bulk offered by Beijing Mesochem Technology

    Find a price of Axitinib bulk offered by Beijing Mesochem Technology

    Find a price of Bacitracin Zinc bulk offered by Beijing Mesochem Technology

    Find a price of Baricitinib bulk offered by Beijing Mesochem Technology

    Find a price of Benzydamine Hydrochloride bulk offered by Beijing Mesochem Technology

    Find a price of Bismuth Potassium Citrate bulk offered by Beijing Mesochem Technology

    Find a price of Brigatinib bulk offered by Beijing Mesochem Technology

    Find a price of Brivaracetam bulk offered by Beijing Mesochem Technology

    Find a price of Cabazitaxel bulk offered by Beijing Mesochem Technology

    Find a price of Cabozantinib bulk offered by Beijing Mesochem Technology

    Find a price of Capmatinib Hydrochloride bulk offered by Beijing Mesochem Technology

    Find a price of Cisatracurium Besylate bulk offered by Beijing Mesochem Technology

    Find a price of Clascoterone bulk offered by Beijing Mesochem Technology

    Find a price of Clindamycin Phosphate bulk offered by Beijing Mesochem Technology

    Find a price of Crisaborole bulk offered by Beijing Mesochem Technology

    Find a price of Crizotinib bulk offered by Beijing Mesochem Technology

    Find a price of Cyclocytidine Hydrochloride bulk offered by Beijing Mesochem Technology

    Find a price of Cytarabine bulk offered by Beijing Mesochem Technology

    Find a price of Dabrafenib Mesylate bulk offered by Beijing Mesochem Technology

    Find a price of Daclatasvir bulk offered by Beijing Mesochem Technology

    Find a price of Dacomitinib bulk offered by Beijing Mesochem Technology

    Find a price of Dapagliflozin bulk offered by Beijing Mesochem Technology

    Find a price of Dasabuvir Sodium bulk offered by Beijing Mesochem Technology

    Find a price of Delafloxacin Meglumine bulk offered by Beijing Mesochem Technology

    Find a price of Dexrazoxane bulk offered by Beijing Mesochem Technology

    Find a price of Docetaxel bulk offered by Beijing Mesochem Technology

    Find a price of Dolutegravir Sodium bulk offered by Beijing Mesochem Technology

    Find a price of Eltrombopag bulk offered by Beijing Mesochem Technology

    Find a price of Eluxadoline bulk offered by Beijing Mesochem Technology

    Find a price of Entrectinib bulk offered by Beijing Mesochem Technology

    Find a price of Enzalutamide bulk offered by Beijing Mesochem Technology

    Find a price of Erdafitinib bulk offered by Beijing Mesochem Technology

    Find a price of Favipiravir bulk offered by Beijing Mesochem Technology

    Find a price of Febuxostat bulk offered by Beijing Mesochem Technology

    Find a price of Fedratinib bulk offered by Beijing Mesochem Technology

    Find a price of Finerenone bulk offered by Beijing Mesochem Technology

    Find a price of Gefapixant Citrate bulk offered by Beijing Mesochem Technology

    Find a price of Granisetron Hydrochloride bulk offered by Beijing Mesochem Technology

    Find a price of Hexamidine bulk offered by Beijing Mesochem Technology

    Find a price of Larotaxel bulk offered by Beijing Mesochem Technology

    Find a price of Larotrectinib Sulfate bulk offered by Beijing Mesochem Technology

    Find a price of Ledipasvir bulk offered by Beijing Mesochem Technology

    Find a price of Lefamulin Acetate bulk offered by Beijing Mesochem Technology

    Find a price of Lenvatinib Mesylate bulk offered by Beijing Mesochem Technology

    Find a price of Lesinurad bulk offered by Beijing Mesochem Technology

    Find a price of Linagliptin bulk offered by Beijing Mesochem Technology

    Find a price of Lorcaserin HCl bulk offered by Beijing Mesochem Technology

    Find a price of Lorlatinib bulk offered by Beijing Mesochem Technology

    Find a price of Methotrexate bulk offered by Beijing Mesochem Technology

    Find a price of Miltefosine bulk offered by Beijing Mesochem Technology

    Find a price of Mitoxantrone bulk offered by Beijing Mesochem Technology

    Find a price of Molnupiravir bulk offered by Beijing Mesochem Technology

    Find a price of Neratinib bulk offered by Beijing Mesochem Technology

    Find a price of Nicotinamide Mononucleotide bulk offered by Beijing Mesochem Technology

    Find a price of Nicotine bulk offered by Beijing Mesochem Technology

    Find a price of Nintedanib Esylate bulk offered by Beijing Mesochem Technology

    Find a price of Niraparib Tosylate bulk offered by Beijing Mesochem Technology

    Find a price of Obeticholic Acid bulk offered by Beijing Mesochem Technology

    Find a price of Odalasvir bulk offered by Beijing Mesochem Technology

    Find a price of Olaparib bulk offered by Beijing Mesochem Technology

    Find a price of Omarigliptin bulk offered by Beijing Mesochem Technology

    Find a price of Osimertinib Mesylate bulk offered by Beijing Mesochem Technology

    Find a price of Paclitaxel bulk offered by Beijing Mesochem Technology

    Find a price of Palbociclib bulk offered by Beijing Mesochem Technology

    Find a price of Pancuronium Bromide bulk offered by Beijing Mesochem Technology

    Find a price of Paritaprevir bulk offered by Beijing Mesochem Technology

    Find a price of Pazopanib Hydrochloride bulk offered by Beijing Mesochem Technology

    Find a price of Pimavanserin Tartrate bulk offered by Beijing Mesochem Technology

    Find a price of Piracetam bulk offered by Beijing Mesochem Technology

    Find a price of Piroctone Olamine bulk offered by Beijing Mesochem Technology

    Find a price of Polymyxin B Sulfate bulk offered by Beijing Mesochem Technology

    Find a price of Prucalopride Succinate bulk offered by Beijing Mesochem Technology

    Find a price of Pyrroloquinoline Quinone Disodium bulk offered by Beijing Mesochem Technology

    Find a price of Raltegravir Potassium bulk offered by Beijing Mesochem Technology

    Find a price of Rasagiline Mesylate bulk offered by Beijing Mesochem Technology

    Find a price of Regorafenib bulk offered by Beijing Mesochem Technology

    Find a price of Remdesivir bulk offered by Beijing Mesochem Technology

    Find a price of Rocuronium Bromide bulk offered by Beijing Mesochem Technology

    Find a price of Roxithromycin bulk offered by Beijing Mesochem Technology

    Find a price of Ruxolitinib Phosphate bulk offered by Beijing Mesochem Technology

    Find a price of